Treating cells with either U-18666A, a compound that creates an NPC-like phenotype, or with bafilomycin A1, a compound that raises late endosomal pH, has no effect on labeling of NPC1-YFP, suggesting that both drugs affect processes other than NPC1 binding to cholesterol. We also developed a procedure to label the NPC1-YFP by [ 3 H]AC in vitro and showed that cholesterol is more effective in protection against labeling than its analogs epicholesterol or 5-␣-cholestan. Overall, the results demonstrate that there is direct binding between NPC1 and azocholestanol; the binding does not require NPC2 but requires a functional SSD within NPC1.
N
iemann-Pick type C (NPC) disease is a fatal neurovisceral disorder characterized by clinically progressive hepatosplenomegaly and central nervous system neurodegeneration (reviewed in ref. 1) . The disease involves the accumulation of unesterified cholesterol, sphingomyelin, glycolipids, and other lipids within the endosomal͞lysosomal system, in cells of various tissues (1) , and in neurons (2) (3) (4) . Currently there is no cure for the disease. The disease can be caused by mutations in either of two genetic loci, NPC1 and NPC2. Mutations in NPC1 account for Ϸ95% of all of the NPC disease cases, whereas mutations at NPC2 account for the remaining Ϸ5% (1).
NPC1 has been extensively studied at the cellular and molecular levels. Chinese hamster ovary (CHO) cells with NPC1 mutations have been isolated, the CT60 and CT43 mutants from 25RA cells (5, 6 ) and other mutants from WT cells (7) (8) (9) . The human NPC1 gene encodes a 1,278-aa (170-190 kDa) glycoprotein, with 13 putative transmembrane domains (TMD) that include a sterol-sensing domain (SSD) located between the third and seventh TMDs (10) . The NPC2 gene encodes a soluble lysosomal protein (11) that can be secreted into the medium and binds cholesterol with high affinity (12) . Single mutations within the putative cholesterol-binding pocket (13) , including the F66A, V96F, and the Y100A mutants, disrupt the ability of the NPC2 to bind cholesterol in vitro (12) .
SSDs consist of Ϸ180 aa organized in five consecutive membrane-spanning domains. NPC1 proteins with single mutations in the SSD, including the Y635C and the P692S mutants, are unable to rescue the cholesterol-trafficking defect present in CT60 cells (14, 15) . The SSD is present in other membrane proteins including hydroxymethylglutaryl (HMG)-CoA reductase (16, 17) , sterol regulatory element-binding protein cleavageactivating protein (SCAP) (18) , PATCHED (19) , and NPC1L1 (20) . Thus, unraveling the mysteries of NPC1 will lead not only to greater knowledge of a devastating human disease, but also to an increased understanding of a family of proteins involved in diverse biological functions, including dietary uptake of cholesterol, mediation of cellular cholesterol homeostasis, and cell-cell signaling (21, 22) .
The native NPC1 protein resides mainly in late endosomes and the related tubulovesicles (15, 23) ; it may interact transiently with lysosomes and the trans-Golgi network (24, 25) . In mutant NPC1 cells, transport of cholesterol to the endosome͞lysosome from low-density lipoprotein (LDL) (26, 27) or from endogenous biosynthesis (2, (28) (29) (30) is partially defective. It has been proposed that NPC1 may be involved in mediating the transport of multiple cargo, including cholesterol, fatty acids, and͞or glycosphingolipids, in late endosomes͞lysosomes (25, 31, 32) . When expressed in Escherichia coli, the NPC1 protein exhibits lipid permease activity and transports fatty acids but not cholesterol (33) . However, there is currently no evidence for NPC1 interacting directly with cholesterol or with other lipids. Photoaffinity labeling has been widely used to demonstrate direct binding between a macromolecule and a specific ligand (reviewed in ref. 34 
Materials and Methods
Plasmids. pREX-NPC1-GFP and pREX-GFP were described in ref. 27 . pNPC1-ECFP, pNPC1-EYFP, and plasmids containing various point mutations of pNPC1-FP were described in ref. 15 . In addition, another point mutation, D945N, was produced. This mutation is found in people with severe NPC disease. pNPC2-myc-his and plasmids containing various point mutations of NPC2-myc-his were described in ref. 12. pVAMP7-YFP was from R. Advani (Stanford University, Stanford, CA).
Cell Culture and Transfection. The CT43 and CT60 mutant cell lines were isolated from mutagenized 25RA cells (5) . Both mutants contain the same gain-of-function mutation in SCAP as the 25RA cells (18) . In addition, the CT mutants contain a premature translational termination mutation near the 3Ј end (for CT43), or near the 5Ј end (for CT60) within the NPC1 coding sequence, producing nonfunctional, truncated NPC1 proteins (6) . The CT60 cells stably expressing the NPC1-YFP protein (CT60-NPC1-YFP cells) have been described (15) . CHO cell lines grown in 100-mm dishes were maintained in medium A (Ham's F-12, plus 10% FBS and 10 g͞ml gentamycin) as monolayers at 37°C with 5% CO 2 . The NPC2-deficient human fibroblast cell line expressing the SV40 large T antigen was from Dr. Yiannis A. Ioannou (37) . Human fibroblasts were grown in the same condition as the CHO cells except that DMEM was used. For CT43 and 25RA cells, transfections with FuGENE 6 (Roche) were carried out. The cells were used for photolabeling within 2 days after transfection. NPC2-deficient human fibroblasts were transfected with 5 g of pNPC1-EYFP and 15 l of Lipofectamine 2000 (Invitrogen) in 8 ml of medium per dish, or cotransfected with 5 g of pNPC1-EYFP, 5 g of pNPC2-mychis, and 30 l of Lipofectamine 2000 in 8 ml of medium per dish. Transfected human fibroblasts were used within 16 h after transfection.
Intact Cell Photolabeling. Transfected cells (3.0 ϫ 10 6 cells unless specified) were grown in medium A for 48 h. Cells were detached by incubating with 10 mM EDTA in Hanks' buffer (unless specified otherwise) at room temperature for 5 min, then pelleted by brief centrifugation into 1.5-ml Eppendorf tubes on ice. After washing with Hanks' buffer, the cell pellets were preincubated with 74.6 l of 5 mM methyl-␤-cyclodextrin (CD; Sigma) for 15 min at 37°C. Next, 56.2 l of the prewarmed The unlabeled sterol͞CD complexes were prepared at 50 mM CD, with sterol͞CD molar ratio at 1:16. CD with or without sterol was prepared in Hanks' buffer. The mixtures (3.0 ϫ 10 6 cells per 300 l final volume) were incubated for 1 h at 37°C, then ice-chilled and subjected to photolysis for 15 min on ice by using the photochemical reaction assembly (from Ace Glass; catalog no. 7825-34), with a 450-watt UV lamp at 366 nm. After photolysis, cells were washed with ice-chilled PBS and pelleted by a microcentrifuge. The pellets were lysed by using 1% Nonidet P-40 lysis buffer [50 mM Tris͞100 mM NaCl͞1% Nonidet P-40͞1 mM EDTA͞1 mM EGTA͞protease inhibitors mixture (Sigma), pH 7.4]. The lysates were subjected to immunoprecipitations (IPs) as described (36) , by using mouse monoclonal anti-GFP antibody (10 g; Abcam 1218 ), mouse monoclonal anti-c-myc antibody [10 g; 9E10 (Roche)], or control mouse IgGs. The immunoprecipitates were subjected to 5-15% gradient SDS͞ PAGE, followed by radioluminography (exposure time, 5 days unless specified). In addition, a parallel set of samples was subjected to 5-15% SDS͞PAGE, followed by immunoblotting with rabbit anti-GFP antibodies (1:10,000; Abcam 290 ) or with rabbit anti-NPC2 antibodies (from P. Lobel, Robert Wood Johnson Medical School, New Brunswick, NJ) as indicated.
LysoTracker Staining in Live Cells and Fluorescence Microscopy. Cells (1.5 ϫ 10 5 cells per well) were grown in medium A on glass coverslips in six-well plates. After washing with PBS, the cells were incubated in F-12 medium containing 150 nM LysoTracker Red (Molecular Probes) for 1 h at 37°C in 5% CO 2 incubator. Afterward, the cells were washed two times with ice-chilled PBS containing 0.1% BSA, and two more times with ice-chilled PBS. The coverslips were quickly mounted with a drop of ProLong Antifade media (Molecular Probes) onto the glass slides. Samples were viewed and photographed by using a Leica TCS SP laser scanning confocal microscope. The images were processed by using LEICA CONFOCAL SOFTWARE (Leica, Deerfield, IL) and quantified by COOLLOCALIZER 1.1.2 (Cytolight Software, Washington, DC).
Preparation of the Membrane Fractions That Contain the NPC1-YFP
Protein. All procedures were performed at 4°C. CT60-NPC1-YFP cells grown in medium A at 80% confluency, in fifteen 150-mm dishes, were scraped into the homogenization buffer (20 mM Hepes͞250 mM sucrose͞1 mM EDTA͞protease inhibitors mixture, pH 7.3), and homogenized by using a stainless steel homogenizer (27) . The postnuclear supernatants were collected after centrifugation (1,000 ϫ g, 5 min) and were subjected to centrifugation (16,000 ϫ g, 40 min) by using a Beckman model 70.1 Ti rotor. The pellets obtained were suspended in the resuspension buffer (50 mM Tris⅐HCl͞150 mM NaCl͞protease inhibitors mixture, pH 7.4), by using a glass homogenizer (Wheaton Scientific; 30 strokes), then repeatedly passed through a 25-gauge needle (10 times). The resuspended membrane fractions were used for the in vitro photolabeling experiments.
In Vitro Photolabeling. The freshly prepared membrane fractions (600 g per sample) were preincubated in a total volume of 263 l per sample, containing 60.0 l of 50 mM CD or 60.0 l of 1.5625 mM unlabeled sterol͞50 mM CD (with sterol at 94.0 nmol), for 20 min at 30°C. CD solutions with or without sterols were prepared in the resuspension buffer. After preincubation, 37.0 l of the prewarmed complex, consisting of 78.1 M were incubated for 1 h at 30°C, ice-chilled, and subjected to photolysis for 15 min on ice as described earlier. After photolysis, the membranes were pelleted by centrifugation (25,000 ϫ g, 30 min) by using a Beckman model 70.1 Ti rotor. The pellets were solubilized by adding 300 l per sample of 2% Nonidet P-40 lysis buffer (50 mM Tris͞100 mM NaCl͞2% Nonidet P-40͞1 mM EDTA͞1 mM EGTA͞protease inhibitors mixture, pH 7.4) and vortexed. The solubilized membrane fractions underwent centrifugation (25,000 ϫ g, 30 min). The supernatants were collected, and subjected to IP by using mouse monoclonal anti-GFP antibody (10 g per sample), or control mouse IgGs (10 g per sample). The immunoprecipitates were subjected to 4-14% gradient SDS͞PAGE. To detect the labeled protein bands, a gel-slicing method (38) was used (instead of the radioluminography method). In brief, after electrophoresis, individual gel lanes were manually cut into 6-mm slices. The sliced gels were placed in glass vials and were dissolved in 0.5 ml per slice of 31% H 2 O 2 by incubating at 70-80°C for 5-6 h. Afterward, 5.0 ml per vial of Ecoscint H (National Diagnosis) was added. After incubation for 12 h at room temperature in a dark room, the radioactivity levels were determined by scintillation counting. In addition, a parallel set of samples after SDS͞PAGE was immunoblotted with rabbit anti-GFP antibodies.
Results

Labeling the NPC1 Protein with [ 3 H]AC in Intact Cells.
It is unknown whether the normal molecular function of NPC1 involves a direct interaction with cholesterol. To answer this question, we first showed that [ 3 H]AC delivered to intact 25RA cells can be esterified and that the percentage of esterification is significantly reduced in the NPC1-deficient CT43 cells (Fig. 6 , which is published as supporting information on the PNAS web site). Thus, the NPC1 protein functionally interacts with AC in intact cells. We next performed intact cell cross-linking experiments. GFP-tagged mouse NPC1 protein was produced in CT43 cells by transient transfection, followed by intact cell photoaffinity labeling using [ 3 H]AC. The results show that, after IP, a single band with the same molecular mass as NPC1-GFP (200 kDa) is specifically photolabeled by [ 3 H]AC ( Fig. 1 B and C, lanes 6 and  11) . The control experiment shows that GFP alone (28 kDa) is not photolabeled by [ 3 H]AC ( Fig. 1 B and C, lanes 5 and 10) .
In separate experiments, we performed intact cell photoaffinity labeling by using [ 3 H]AC in cells transiently transfected with the YFP-tagged late endosomal membrane protein Vamp7 (39) . The result showed that Vamp7-YFP was not labeled by [ 3 H]AC (Fig. 1B, lane 9) . The expression level of the Vamp7-YFP is near that of NPC1-YFP (compare lanes 12 and 13 of Fig.  1C ). Both NPC1 and Vamp7 are membrane proteins located mainly in late endosomes; Vamp7 contains one predicted transmembrane domain near its C terminus (39) . Thus, the interaction between [ 3 H]AC and NPC1 is not simply due to the overexpression of an integral membrane protein that resides within late-endosomal membranes. unpublished data). For the two NPC1 proteins that contain point mutations within the SSD [P692S and Y635C (15)], the results show much diminished labeling ( Fig. 2A) . In the third mutant (D945N), which contains a point mutation outside the SSD, the labeling is not diminished. These results suggest that the difference in labeling between the WT and the two SSD mutant NPC1 is not simply due to the loss of function of the two SSD mutants. To strengthen these results, in a separate experiment, we used 25RA cells instead of CT43 cells as the host for expression and compared the labeling of the WT and the two SSD mutants. The 25RA cells contain an active, endogenous NPC1, whereas the CT43 cells do not. We obtained the same result as in CT43 cells (Fig. 2 A Right) . These data indicate that the difference in labeling between the WT and the two mutant SSD NPC1 proteins does not depend on whether the host cells contain a functional NPC1. Further experiments on protein localization were done to address the possibility that the different amounts of cross-linking with mutant vs. WT NPC1 proteins were due to changes in their subcellular localizations. WT NPC1 is localized mainly in late endosomes, whereas certain mutant NPC1s are mislocalized to the endoplasmic reticulum (ER) (15) . LysoTracker is a fluorescent dye that mainly stains the highly acidic subcellular organelles, i.e., the late endosomes͞lysosomes, in live cells. We compared the degree of colocalization between various NPC1s and LysoTracker in CT43 cells. The results show that WT NPC1 and the P692S mutant protein significantly colocalize with LysoTracker ( Fig. 2B Upper Left and Lower Left, 55% and 51%, respectively). The Y635C mutant colocalizes much less with LysoTracker ( Fig. 2B Upper Right, 27%) . The D945N mutant also significantly colocalizes with the LysoTracker (Fig. 2B Lower Right, 55%). Results similar to those shown in Fig. 2 were obtained when 25RA cells were used as the host for expression (results not shown). Thus, the large difference in [ 3 H]AC labeling between the WT NPC1 and the P692S mutant NPC1 (Fig. 2 A) is unlikely to be accounted for by the small difference in their intracellular localizations (Fig. 2B) (Fig. 3) . These results further support the interpretation that the labeling seen by using our procedure is based on AC behaving as an analog of cholesterol.
It has been proposed that NPC2 may be necessary to mediate the interaction between NPC1 and cholesterol (for example, ref. 40) . To address this question, we expressed NPC1 alone or with NPC2 in a mutant human fibroblast cell line known to lack NPC2 (37) and then performed intact cell labeling with [ (Fig.  4) . Thus, binding between AC and NPC1 does not require NPC2. After labeling, the membranes were solubilized by detergent; the NPC1-YFP was then isolated by IP followed by SDS͞PAGE. To evaluate the labeling more precisely, we quantitated the labeling by gel slicing. The results showed (Fig. 5A ) that NPC1-YFP can be labeled by [ 3 H]AC in vitro and that excess CD present in the labeling mixture does not significantly affect the extent of labeling. By using this procedure, we next tested the abilities of various unlabeled steroids, added in excess as a CD complex, to protect against labeling. The results showed that cholesterol is more effective in protection than its analog epi-cholesterol (a sterol with the OH-moiety at ␣ orientation), or 5-␣ cholestan (a steroid without the OH-moiety at C-3). Thus, the NPC1 protein may contain a specific binding site(s) that recognizes the 3-␤ OH moiety of the steroid ring. We also noted that cholesterol present in 30-fold excess only partially inhibited the [ 3 H]AC labeling (by 30%; results seen in two experiments). Thus, NPC1 may bind cholesterol with low affinity.
Labeling of NPC1-YFP by [ 3 H]AC in Vitro and
Effects of Various Agents on Labeling Between NPC1 Protein and
[ 3 H]AC in Intact Cells. U-18666A is a hydrophobic compound that produces an NPC phenotype in treated cells (41) . One mode of its action could be to compete with the association of cholesterol with NPC1. Adding U-18666A to CT60-NPC1-YFP cells for a short period (15 min) or for a long period (36 h) before cross-linking causes no significant alteration in the degree of labeling in intact cells (Fig. 7A , which is published as supporting information on the PNAS web site). Thus, the binding between AC and NPC1 is not altered by U-18666A. NPC1 seems to be a distant member of the RND permease family that functions through a proton-antiport mechanism (33) . Thus, disrupting the proton gradient might interfere with labeling. To test this possibility, we found that treating cells with bafilomycin A1, a compound that interferes with vacuolar H ϩ -ATPase and raises endosomal͞lysosomal pH (42) , caused no significant alteration in degree of labeling intact cells (Fig. 7B) Two ideas about mechanism arise from the binding of sterol to NPC1. (i) NPC1 binds to cholesterol as its substrate and transports it at the late endosomal membrane; this possibility would be consistent with the current finding that NPC1 binds to cholesterol with low affinity. (ii) NPC1 participates in transporting various substances͞complexes at the endosomal membrane; its activity is modulated by cholesterol bound as an allosteric regulator. These two possibilities are not mutually exclusive, and further investigations are required for resolution. If NPC1 transports cholesterol, it apparently does not use NPC2 bound to cholesterol as a donor for binding cholesterol. Additional results presented here indicate that a functional SSD is required for NPC1 to bind [ 3 H]AC. To our knowledge, the current report provides the first evidence that a protein containing an SSD directly binds to a cholesterol analog. Several proteins, among others, contain SSDs: (i) HMG-CoA reductase, a ratecontrolling enzyme in cholesterol biosynthesis (43) ; (ii) SCAP, a protein that forms a complex with the SRE binding proteins (SREBPs) and translocates from the endoplasmic reticulum (ER) to the Golgi in response to cholesterol deprivation in the ER (44); (iii) PATCHED, a tumor suppressor involved in the signal transduction cascade mediated by the cholesterolmodified morphogen Hedgehog (19) ; and (iv) NPC1L1, a protein recently reported to be involved in intestinal cholesterol absorption (20) . These proteins all participate in various cholesterol-dependent regulatory events in some manner, and the SSDs present in these proteins play important roles in mediating the functions of these proteins (reviewed in ref. 22 ). On the other hand, whether binding occurs between sterol(s) and any of these SSD proteins and, if so, whether an SSD is required have not 
